| User's Publication |
|
21829
Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N.
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.
Science
2024
385(6705):eadl6173
PubMed ID: 38991060
DOI: 10.1126/science.adl6173
|
|
21886
Schüler J, Vockerodt M, Salehzadeh N, Becker J, Wilting J.
Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis.
Curr Issues Mol Biol
2024
46(7):7395-7410
PubMed ID: 39057080
DOI: 10.3390/cimb46070439
|
|
21103
Shi L, Shen W, Davis MI, Kong K, Vu P, Saha SK, Adil R, Kreuzer J, Egan R, Lee TD, Greninger P, Shrimp JH, Zhao W, Wei TY, Zhou M, Eccleston J, Sussman J, Manocha U, Weerasekara V, Kondo H, Vijay V, Wu MJ, Kearney SE, Ho J, McClanaghan J, Murchie E, Crowther GS, Patnaik S, Boxer MB, Shen M, Ting DT, Kim WY, Stanger BZ, Deshpande V, Ferrone CR, Benes CH, Haas W, Hall MD, Bardeesy N.
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers.
Nat Cancer
2023
PubMed ID: 36914816
DOI: 10.1038/s43018-023-00523-0
|
|
21205
Mohan A, Griffith KA, Wuchu F, Zhen DB, Kumar-Sinha C, Crysler O, Hsiehchen D, Enzler T, Dippman D, Gunchick V, Achreja A, Animasahun O, Choppara S, Nenwani M, Chinnaiyan AM, Nagrath D, Zalupski MM, Sahai V.
Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04).
Clin Cancer Res
2023
PubMed ID: 37115501
DOI: 10.1158/1078-0432.CCR-23-0036
|
|
21288
Pan YR, Wu CE, Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH, Hung TH, Yu AL, Huang WK, Yeh CN.
Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Int J Biol Sci
2023
19(9)2772-2786
PubMed ID: 37324940
DOI: 10.7150/ijbs.79126
|
|
21390
Chen CP, Yeh CN, Pan YR, Huang WK, Hsiao YT, Lo CH, Wu CE.
Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer.
Biomed Pharmacother
2023
166:115389
PubMed ID: 37659202
DOI: 10.1016/j.biopha.2023.115389
|
|
21456
Toshida K, Itoh S, Iseda N, Izumi T, Yoshiya S, Toshima T, Ninomiya M, Iwasaki T, Oda Y, Yoshizumi T.
Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma.
Cancer Sci
2023
PubMed ID: 37878531
DOI: 10.1111/cas.15981
|
|
20420
Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, Zhang MS, Ng IO, Wong CC.
Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
Hepatol Commun
2022
PubMed ID: 34558800
DOI: 10.1002/hep4.1682
|
|
20893
Jamnongsong S, Kueanjinda P, Buraphat P, Sakornsakolpat P, Vaeteewoottacharn K, Okada S, Jirawatnotai S, Sampattavanich S.
Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma.
iScience
2022
25(10):105182
PubMed ID: 36248745
DOI: 10.1016/j.isci.2022.105182
|
|
21148
Kosai-Fujimoto Y, Itoh S, Yugawa K, Fukuhara T, Okuzaki D, Toshima T, Harada N, Oda Y, Yoshizumi T, Mori M.
Impact of JMJD6 on intrahepatic cholangiocarcinoma.
Mol Clin Oncol
2022
17(2):131
PubMed ID: 35911665
DOI: 10.3892/mco.2022.2564
|
|
13539
Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK.
Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis
Dig Dis Sci
2021
66(4):1080-1089
PubMed ID: 32445050
DOI: 10.1007/s10620-020-06330-2
|
|
14929
Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, Fujimoto M, Uemura S, Namikawa T, Murakami I, Kobayashi S, Eguchi H, Doki Y, Hanazaki K, Naka T.
Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1 positive cholangiocarcinoma
Mol Cancer Ther
2021
molcanther.0015.2021
PubMed ID: 34224365
DOI: 10.1158/1535-7163.MCT-21-0015
|
|
15502
Weng SW, Liu TT, Eng HL, You HL, Huang WT.
Autophagy Plays a Role in the CUL4A-Related Poor Prognosis of Intrahepatic Cholangiocarcinoma
Pathol Oncol Res
2021
27:602714
PubMed ID: 34257560
DOI: 10.3389/pore.2021.602714
|
|
12014
Somchai P, Phongkitkarun K, Kueanjinda P, Jamnongsong S, Vaeteewoottacharn K, Luvira V, Okada S, Jirawatnotai S, Sampattavanich S.
Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors.
Sci Rep
2020
PubMed ID: 31969633
DOI: 10.1038/s41598-020-57806-0
|
|
13336
Pan YR, Wu CE, Yeh CN.
ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.
Biomolecules
2020
PubMed ID: 33182492
DOI: 10.3390/biom10111529
|
|
12588
Yoh T, Hatano E, Kasai Y, Fuji H, Nishi K, Toriguchi K, Sueoka H, Ohno M, Seo S, Iwaisako K, Taura K, Yamaguchi R, Kurokawa M, Fujimoto J, Kimura T, Uemoto S, Nishi E.
Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection
Clin Cancer Res
2019
25(2):619-628
PubMed ID: 30352908
DOI: 10.1158/1078-0432.CCR-18-0124
|
|
12589
Miyata T, Yamashita YI, Yoshizumi T, Shiraishi M, Ohta M, Eguchi S, Aishima S, Fujioka H, Baba H.
CXCL12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis
Cancer Sci
2019
110(10):3197-3203
PubMed ID: 31361379
DOI: 10.1111/cas.14151
|
|
14816
Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma
Cancer Discov
2019
9(8):1064-1079
PubMed ID: 31109923
DOI: 10.1158/2159-8290.CD-19-0182
|
|
11220
You HL, Liu TT, Weng SW, Chen CH, Wei YC, Eng HL, Huang WT.
Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma.
Oncol Lett
2018
PubMed ID: 30250623
DOI: 10.3892/ol.2018.9284
|
|
4347
Lin HY, Tey SL, Ho Y, Chin YT, Wang K, Whang-Peng J, Shih YJ, Chen YR, Yang YN, Chen YC, Liu YC, Tang HY, Yang YS.
Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway.
Mar Drugs
2018
PubMed ID: 30563284
DOI: 10.3390/md16120489
|
|
14913
Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
Dis Model Mech
2018
11(8):dmm03305
PubMed ID: 29666220
DOI: 10.1242/dmm.033050
|
|
10290
Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Mol. Carcinog.
2017
56:2146-2157
PubMed ID: 28467612
DOI: 10.1002/mc.22671
|
|
10333
Huang G-, Liu TT, Weng SW, You HL, Wei YC, Chen CH, Eng HL, Huang WT.
CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma.
BMC Cancer
2017
17:395
PubMed ID: 28576144
DOI: 10.1186/s12885-017-3389-z
|
|
10501
Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, Nakamura T, Tsuchikawa T, Okamura K, Ishizuka M, Hirano S.
5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice.
In Vivo
2017
31:905-908
PubMed ID: 28882957
DOI: 10.21873/invivo.11145
|
|
9871
Hoshino H, Ohta M, Ito M, Uchimura K, Sakai Y, Uehara T, Low S, Fukushima M, Kobayashi M.
Apical membrane expression of distinct sulfated glycans represents a novel marker of cholangiolocellular carcinoma.
Lab. Invest.
2016
96:1246-1255
PubMed ID: 27748735
DOI: 10.1038/labinvest.2016.104
|
|
3735
Saha SK et al
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cancer Discov
2016
6(7):727-39
PubMed ID: 27231123
DOI: 10.1158/2159-8290.CD-15-1442
|
|
5025
Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H.
Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.
Cancer Sci
2015
106(9):1153-62
PubMed ID: 26132727
DOI: 10.1111/cas.12732
|
|
9170
Sheng-Huei Yang 1, Hung-Yun Lin, Vincent H S Chang, Chien-Chung Chen, Yun-Ru Liu, Jinghan Wang, Keqiang Zhang, Xiaoqing Jiang, Yun Yen
Lovastatin Overcomes Gefitinib Resistance Through TNF-α Signaling in Human Cholangiocarcinomas With Different LKB1 Statuses in Vitro and in Vivo
Oncotarget
2015
6 (27), 23857-73
PubMed ID: 26160843
DOI: 10.18632/oncotarget.4408
|
|
15203
Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y.
Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma
Oncotarget
2015
6(22):18905-20
PubMed ID: 26056085
DOI: 10.18632/oncotarget.4305
|
|
12541
Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.
ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma
Hepatol Res
2014
44(14):E320-34
PubMed ID: 24552196
DOI: 10.1111/hepr.12312
|
|
18596
Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, Kikuchi K, Yamada G, Suzuki K, Honda J, Wilson-Morifuji M, Araki N, Eto M, Baba H, Imamura T.
Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88)
Clin Cancer Res
2013
19(8):2004-13
PubMed ID: 23287562
DOI: 10.1158/1078-0432.CCR-12-1204
|
|
12544
Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T.
Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma
Hepatol Res
2013
43(9):959-69
PubMed ID: 23369163
DOI: 10.1111/hepr.12047
|
|
14852
Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
Gastroenterology
2012
142(4):1021-1031.e15
PubMed ID: 22178589
DOI: 10.1053/j.gastro.2011.12.005
|
|
8365
Ishii T, Yasuchika K, Suemori H, Nakatsuji N, Ikai I, Uemoto S.
Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma.
Cancer Lett.
2010
294:25-34
PubMed ID: 20149523
DOI: 10.1016/j.canlet.2010.01.019
|
|
19310
Takayama Y, Kokuryo T, Yokoyama Y, Ito S, Nagino M, Hamaguchi M, Senga T.
Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis
Cancer Lett
2010
296(1):27-34
PubMed ID: 20381954
DOI: 10.1016/j.canlet.2010.03.011
|
|
6410
Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.
Is parainfluenza virus a threatening virus for human cancer cell lines?
Hum Cell
2009
22(3):81-4
PubMed ID: 19624309
DOI: 10.1111/j.1749-0774.2009.00071.x
|
|
18314
Tanaka Y, Kanai F, Tada M, Tateishi R, Sanada M, Nannya Y, Ohta M, Asaoka Y, Seto M, Shiina S, Yoshida H, Kawabe T, Yokosuka O, Ogawa S, Omata M.
Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma
J Hepatol
2008
49(5):746-57.
PubMed ID: 18752864
DOI: 10.1016/j.jhep.2008.06.019
|
|
18693
Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S.
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer
Gastroenterology
2008
135(4):1358-1368
PubMed ID: 18692501
DOI: 10.1053/j.gastro.2008.06.082
|
|
3575
Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T.
Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma.
Hepatology
2008
47(3):888-96
PubMed ID: 18306229
DOI: 10.1002/hep.22125
|
|
3335
Yoshino K, Iimura E, Saijo K, Iwase S, Fukami K, Ohno T, Obata Y, Nakamura Y.
Essential role for gene profiling analysis in the authentication of human cell lines.
Hum Cell
2006
19(1):43-8
PubMed ID: 16643607
DOI: 10.1111/j.1749-0774.2005.00007.x
|
|
3077
Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol Cancer Ther
2005
4:399-412
PubMed ID: 15767549
DOI: 10.1158/1535-7163.MCT-04-0234
|
|
3334
Obama, Kazutaka, Ura, Katsuaki, Satoh, Seiji, Nakamura, Yusuke, Furukawa, Yoichi
Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma
Oncol Res
2005
14:701-706
PubMed ID: 16077978
|
|
3346
Yokoo, Hideki, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Todo, Satoru, Hirohashi, Setsuo
Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells.
Hepatology
2004
40:609-17
PubMed ID: 15349899
DOI: 10.1002/hep.20372
|
|
3703
Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J.
Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers.
Cancer Sci
2004
95(12):969-76
PubMed ID: 15596046
DOI: 10.1111/j.1349-7006.2004.tb03185.x
|
|
15587
Tanaka S, Iwai M, Harada Y, Morikawa T, Muramatsu A, Mori T, Okanoue T, Kashima K, Maruyama-Tabata H, Hirai H, Satoh E, Imanishi J, Mazda O.
Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter
Cancer Gene Ther
2000
7(9):1241-50
PubMed ID: 11023196
DOI: 10.1038/sj.cgt.7700219
|
Back
Top
CELL BANK Website
